Antibody treatment for Alzheimer's disease guided by brain scans
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a monoclonal antibody drug can help people with early Alzheimer's disease or mild cognitive impairment. The drug targets amyloid plaques in the brain, which are detected using a special PET scan before treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild cognitive impairment or mild-to-moderate Alzheimer's disease, with a positive amyloid PET scan.
- You are between 50 and 85 years old.
- You are not currently in another clinical trial.
- You can provide written consent and follow the study plan.
- You do not have any condition that makes MRI unsafe, like metal implants or severe claustrophobia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study compares different doses of the drug lecanemab to see how well they work in people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to find the best dose for slowing memory decline in real-world settings.
This study tests whether using a stronger MRI scanner can help make antibody treatments for early Alzheimer's disease work better. If you are already eligible for and starting such a treatment, this study may help track how well it's working.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.